Related Experiment Video

Updated: Dec 30, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

871

Notch inhibitor mitigates renal ischemia‑reperfusion injury in diabetic rats

Xiaokai Duan1, Guijun Qin1

  • 1Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.

Molecular Medicine Reports
|January 25, 2020
PubMed

Insights

The Notch inhibitor DAPT mitigates renal ischemia-reperfusion injury in diabetic rats by improving kidney function and enhancing antioxidative activity. This suggests DAPT as a potential therapy for diabetic kidney injury.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus exacerbates renal ischemia-reperfusion (I/R) injury.
  • Notch signaling pathway is implicated in renal disorders.

Purpose of the Study:

  • To evaluate the protective effect of the Notch inhibitor DAPT on renal I/R injury in a streptozocin-induced diabetic rat model.
  • To investigate the underlying mechanisms involving anti-oxidation and HIF-1a.

Main Methods:

  • Streptozocin-induced diabetic rats were used and divided into treatment groups.
  • Renal I/R injury was induced, and animals were preconditioned with DAPT to inhibit Notch signaling.
  • Renal function, oxidative stress markers, inflammatory factors, and HIF-1a expression were assessed.

Main Results:

  • DAPT treatment significantly mitigated renal injury and improved renal function in diabetic rats.
  • Antioxidative activity was markedly enhanced, and HIF-1a was upregulated in DAPT-treated rats.
  • These findings suggest a protective role of DAPT against renal I/R injury in diabetes.

Conclusions:

  • The Notch inhibitor DAPT demonstrates a therapeutic potential for improving outcomes of renal I/R injury in diabetic rats.
  • DAPT's protective effects are partly mediated through the regulation of anti-oxidation and HIF-1a.
  • DAPT represents a promising therapeutic target for managing diabetic kidney injury.
Keywords:
diabetes mellitusnotchsecretase inhibitorN‑[N‑(3,5‑difluorophenacetyl)‑L‑alanyl]‑S‑phenylglycine t‑butyl esterstreptozocin model

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K
Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

10.2K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
844